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Original Article
Cell Type Impacts Accessibility of mRNA
to Silencing by RNA Interference
Chantal M. Ferguson,1 Dimas Echeverria,1 Matthew Hassler,1 Socheata Ly,1 and Anastasia Khvorova1
1RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA 01605, USA
RNA interference (RNAi) is a potent mechanism that silences
mRNA and protein expression in all cells and tissue types.
RNAi is known to exert many of its functional effects in the
cytoplasm, and thus, the cellular localization of target mRNA
may impact observed potency. Here, we demonstrate that cell
identity has a profound impact on accessibility of apolipopro-
tein E (ApoE) mRNA to RNAi. We show that, whereas both
neuronal and glial cell lines express detectable ApoE mRNA,
in neuronal cells, ApoE mRNA is not targetable by RNAi.
Screening of a panel of thirty-five chemically modified small
interfering RNAs (siRNAs) did not produce a single hit in a
neuronal cell line, whereas up to fifteen compounds showed
strong efficacy in glial cells. Further investigation of the cellular
localization of ApoE mRNA demonstrates that ApoE mRNA is
partially spliced and preferentially localized to the nucleus
(80%) in neuronal cells, whereas more than 90% of ApoE
mRNA is cytoplasmic in glial cells. Such an inconsistency in
intracellular localization and splicing might provide an expla-
nation for functional differences in RNAi compounds. Thus,
cellular origin might have an impact on accessibility of
mRNA to RNAi and should be taken into account during the
screening process.
INTRODUCTION
mRNA silencing via RNA interference (RNAi) is a potent mecha-
nism that silences gene expression in all cell and tissue types. Chem-
ically modified small interfering RNAs (siRNAs) are small, double-
stranded oligonucleotides that load into the RNA-induced silencing
complex (RISC) and target mRNA for cleavage and degradation
prior to translation into protein.1 Antisense oligonucleotides
(ASOs) cause mRNA silencing via both nuclear and cytoplasmic
RNase H.1 Whereas RNAi machinery is present in both the cyto-
plasm and the nucleus, the degree of efficacy has been shown to
be much higher in the cytoplasm.2,3 Whereas it is possible that the
cellular localization of mRNA (nuclear or cytoplasmic) may impact
the accessibility of mRNA to RNAi, other studies show clear exam-
ples of potent RNAi in the nucleus,4 thus suggesting alternative
mechanisms of apolipoprotein E (ApoE) mRNA resistance to
RNAi, such as intron retention.
The mechanism of RNAi is very well characterized and understood,5,6
with many algorithms developed for predicting siRNA efficacy.7 In
general, it is believed that the dominant factor defining siRNA activity
is efficient RISC loading, followed by proper accommodation for
enzymatic cleavage and product release and some contribution
from target-site accessibility. Thus, compounds identified in one
cellular background have a tendency to be active across cell types
and tissues, with rare exceptions. As a result, the generic screening
strategy relies on identification of an easily expandable cell line
with reasonable target expression levels for the primary screen,
following with hit validation in relevant cells and in vivo.
We screened a panel of fully modified siRNAs (35) targeting ApoE in
two different cell lines—mouse neuroblastoma 2a (N2A) cells and
mouse primary astrocytes—and observed stark differences in effi-
cacy. ApoE, a member of the larger family of lipoproteins, is ex-
pressed and functions in distinct physiological compartments.8 Sys-
temic ApoE is secreted mainly by hepatocytes and facilitates lipid
uptake into peripheral tissues via low-density lipoprotein (LDL) re-
ceptors.9,10 In the central nervous system (CNS), ApoE is expressed
by astrocytes and to a lesser extent, neurons, to transport lipids be-
tween cells and modulate the inflammatory response.11–14 Previous
studies suggest that whereas the basal expression of ApoE is rela-
tively low in neurons compared to glial cells, neuronal ApoE is acti-
vated in response to injury or inflammation. Upon activation,
incompletely spliced ApoE pre-mRNA may mature into mRNA
and is transported from the nucleus to the cytoplasm.11,12 This phe-
nomenon is not unique to ApoE: intron retention as a mechanism
for controlling gene expression is well documented and observed
in neuronal cells.15
With the use of advanced fluorescence in situ hybridization (FISH),
we show that whereas both cells of neuronal and glial origin express
ApoE mRNA, the expression levels and cellular localization (nuclear
versus cytoplasm) of ApoE vary between cell types, potentially im-
pacting accessibility to RNAi. Furthermore, with the use of RNA
sequencing (RNA-seq), we show that ApoE mRNA in N2A cells
may not be completely spliced, suggesting that intron retention
may be an additional mechanism by which ApoE mRNA resists
silencing.
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RESULTS
Cell Type Impacts Efficacy of siRNAs Targeting ApoE
We designed and synthesized a panel of thirty-five fully modified,
cholesterol-conjugated siRNAs targeting all regions (50 UTR, open
reading frame [ORF], 30 UTR) of mouse ApoE mRNA. Inclusion of
a cholesterol conjugate allows for passive uptake of siRNAs into cells
and mitigates the need for lipid-mediated transfection.16We tested all
ApoE-targeting siRNAs in mouse N2A cells at a 1.5-mM concentra-
tion and observed that none of the thirty-five compounds induced
silencing of ApoE mRNA (Figure 1A). To identify efficacious
siRNAs, we designed several sequences per gene, following the rules
laid out in Birmingham et al.17 The typical hit rate for this chemical
configuration in the context of advanced bioinformatics algorithms
differs between different genes but ranges between 10% and 40%.
Therefore, it is highly unusual that none out of thirty-five sequences
would be efficacious.
For initial screening, we used a well-established and validated assay:
QuantiGene. This assay serves as a high-throughput, ELISA-like
method for quantifying mRNA and identifying efficacious siRNAs
by measuring target RNA directly from cell or tissue lysates in a
96-well plate format.18,19 With the use of probe sets specific for mouse
ApoE, we observed specific detection of ApoE mRNA in N2A cells,
with proportional increase in signal as the volume of lysate was
increased (Figure 1B), defining the broad linear range of the signal.
To ensure that lack of siRNA efficacy was not due to a nonspecific
signal, we confirmed ApoE expression in N2A cells using qRT-PCR
on purified RNA. Similar to results observed using QuantiGene,
ApoE mRNA was detectable using qRT-PCR in a concentration-
dependent manner (Figure 1C). In both qRT-PCR and QuantiGene,
theApoEmRNA expression level was normalized to the housekeeping
gene Ppib to control for variances in cell number or lysate volume.
Additionally, we confirmed expression of processedApoE in N2A cells
using previously published RNA-seq datasets (Figure 1D).20 ApoE
mRNA was easily detected at 8.1 transcripts per million (TPM) (Fig-
ure 1D), showing typical exon/intron distribution density with excep-
tion of intron 1. Thus, ApoE mRNA is expressed in N2A cells, and
the absence of observable efficacy with any of the thirty-five tested
compounds may not be explained by lack of probe specificity.
In vivo, astrocytes have a higher expression level ofApoE compared to
neurons. To determine if cell identity had an impact on siRNA effi-
cacy, we screened the same thirty-five fully modified siRNAs targeting
ApoE in mouse primary astrocytes (Figure 1E). Both QuantiGene and
qRT-PCR efficiently detected ApoE mRNA expression with a wide
linear range, albeit at a much higher level than in N2A cells (Figures
1F and 1G). RNA-seq data confirmed expression in astrocytes at sub-
stantially higher levels (17,000 TPM), with no reads mapping to the
first intron (Figure 1H).21
In contrast to N2A cells, in mouse primary astrocytes, six (17%) and
fifteen (43%) out of thirty-five siRNAs silenced ApoE mRNA expres-
sion by more than 90% and 50%, respectively (Figure 1E). The
observed hit rate of more than 17% correlates with previous experi-
ence in screening siRNAs.
To see if a reduction in chemical modifications and increased passen-
ger strand dissociation impacted accessibility to RNAi,22 we synthe-
sized the same panel of siRNAs with conserved 20 hydroxyl ribose
at positions four, five, and six of the sense strand (Table S2). Reduc-
tion in chemical modification of the sense strand did not impact the
efficacy of siRNAs targeting ApoE in either N2A cells (Figure S2A) or
mouse primary astrocytes (Figure S2B). These results suggest that
resistance to degradation via RNAi may not be due to the complete
chemical modification of siRNAs. Future studies are necessary to
determine if completely unmodified siRNAs demonstrate similar
results.
We demonstrate that whereas both N2A cells and astrocytes express
ApoE, although at different amounts, the ability of siRNAs to access
and silence ApoE mRNA is meaningfully affected by cell type.
We have previously shown that cellular origin has an impact on sub-
cellular localization of huntingtin mRNA in both wild-type mice23
and mutant models of Huntington’s disease models. We found that
in cells of neuronal origin, a larger portion ofHttmRNAwas localized
to the nucleus, corresponding to a lower degree of observable mRNA
silencing.23 Thus, as a next step, we evaluatedApoE intracellular local-
ization in different cell types.
ApoE mRNA Expression Level and Localization Vary between
Cell Type
To visually detect ApoE mRNA and investigate its cellular localiza-
tion, we used an advanced version of FISH technology, RNAscope.
RNAscope requires sequential binding of multiple Z probes that are
complementary to the target mRNA, ensuring highly specific binding.
Next, a branched DNA amplification system allows for the detection
of single RNA molecules in cells with high resolution and sensi-
tivity.24 With the use of fluorescent imaging, it is possible to visualize
individual mRNA foci and quantify relative nucleus or cytoplasm
localization.
With the use of RNAscope, ApoE mRNA foci were detected in both
nucleus and cytoplasm with5 (±4) and 2 (±3) copies in the nucleus
and cytoplasm, respectively (Figures 2A and 2B). The cumulative per-
cell number of foci correlated well with qRT-PCR and QuantiGene
(Figures 1B and 1C). The nuclear-to-cytoplasmic ratio of ApoE
mRNA was80% (Figure 2B). With the assumption that the nuclear
fraction of mRNA is less accessible to RNAi in the experimental time
frame (3 days), preferential nuclear localization may explain the lack
of observable silencing.
In primary mouse astrocytes, consistent with qRT-PCR and
QuantiGene data, RNAscope showed a high amount of ApoE
mRNA expression in both the nucleus and the cytoplasm (Fig-
ure 2C), with >90% of mRNA showing cytoplasmic localization
(Figure 2D).
www.moleculartherapy.org
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Figure 1. Efficacy of siRNAs Targeting ApoE Is Impacted by Cell Line Despite mRNA Expression
(A) Screen of 35 fully modified siRNAs in mouse N2A cells. Previously validated siRNAs targeting HTT and PPIB were used as positive controls for screening assays. (B and F)
mRNA expression (relative light unit [RLU]) versus cell lysate volume using the QuantiGene branched DNA (bDNA) assay for mRNA expression in N2A (B) or primary astrocytes
(F). (C and G) ApoEmRNA expression in N2A cells (C) and astrocytes (G) versus RNA concentration using qRT-PCR. (E) Screen of same 35 fully modified siRNAs in mouse
primary astrocytes. (D and H) Analysis of RNA-seq datasets confirming expression of ApoE mRNA in N2A (D) and primary astrocytes (H).
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To see if expression patterns were similar in vivo, we examined
ApoE mRNA expression in wild-type mouse brain samples using a
modified version of RNAscope/immunofluorescence. Staining for
NeuN was used to define neuronal cells. Qualitatively, we observed
analogous distribution of ApoE mRNA in neuronal and non-
neuronal cells (Figures 2E and 2F), where glial cells expressed sub-
stantially higher amounts of ApoE mRNA with clear cytoplasmic
preference.
Dose-Dependent Reduction of ApoE Observed in Mouse
Primary Astrocytes
Visualization of mRNA silencing using RNAscope shows no
detectable effect on ApoE expressed in N2A cells (Figures 3A
A B
DC
E F
Figure 2. Increased Nuclear Localization of ApoE
mRNA in Neuronal Cells
(A and C) ApoEmRNA (green) in (A) mouse N2A cells and
(C) primary astrocytes (HPRT in red). (B and D) Quantifi-
cation of nuclear and cytoplasmic mRNA foci in (B) N2A
cells and (D) primary astrocytes (% of total foci). (E) ApoE
mRNA (green) in wild-type mouse brain, with NeuN (red)
marking neuronal cells. (F) Zoom (arrows) of wild-type
mouse brain showing qualitative increase in ApoE mRNA
in non-neuronal (NeuN-negative) cells and preferential
cytoplasmic localization. Scale bars, 10 mm. Statistical
analysis: t-tests using GraphPad Prism. Error bars are SD.
(**** p <0.0001; *** p<0.002; ** p<0.01; * p<0.05).
and 3B), whereas an almost-complete reduc-
tion of ApoE in astrocytes was observed (Fig-
ures 3C and 3D). To explore the impact of
cell type on RNAi efficacy in more detail,
we performed dose-response studies using
lead siRNA sequences: APOE1134 and
APOE1203. Both compounds (in an eight-
point dose response) showed no detectable
silencing in N2A cells (Figure 3E), whereas
there was clear dose-dependent reduction of
ApoE mRNA expression in primary astrocytes
(Figure 3F). In addition, we treated both N2A
cells and primary astrocytes with 3 doses of
lead siRNA (APOE1134) and evaluated
silencing using qRT-PCR (Figure 3H). Once
again, we observed dose-dependent silencing
in primary astrocytes but no silencing in
N2A cells (Figure 3H), suggesting that the
lack of observed silencing in N2A cells is
not due to the method used to quantify
mRNA. On a protein level, we observed a
dose-dependent reduction of APOE protein
expression in primary astrocytes (treatment
with APOE1134 versus nontargeting control
[NTC]) (Figure 3G). Interestingly, despite
the presence of ApoE mRNA (Figures 1 and
3A), the APOE protein expression in a N2A
cell was below the level of detection (Figure 3G, top). Taken
together, these observations are consistent with the large body of
literature that supports glial cells as the primary source of CNS
ApoE expression.11,12,25
Thus, N2A cells express detectable ApoE mRNA at 7 foci
per cell (RNAscope), and mRNA is detectable by QuantiGene,
qRT-PCR, and RNA-seq (Figure 1). Even though ApoE mRNA
is properly spliced in N2A cells, it is preferentially (80%) localized
to the nucleus (Figure 1D). Interestingly, whereas ApoE mRNA
is expressed and detected, it is not efficiently translated, as
the amount of APOE protein is below the level of detection and is
not readily accessible to RNAi in all doses tested.
www.moleculartherapy.org
Molecular Therapy: Nucleic Acids Vol. 21 September 2020 387
Figure 3. Dose-Dependent Reduction of ApoE Only in Primary Astrocytes
(A) RNAscope showing no change in ApoEmRNA foci between N2A cells treated with nontargeting control (NTC) and ApoE-targeting siRNA (APOE1134). (B) Quantification of
neuronal and cytoplasmic ApoEmRNA foci in N2A cells. (C) RNAscope showing reduction of ApoEmRNA in primary astrocytes after treatment with ApoE-targeting siRNA
(legend continued on next page)
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Therefore, intron retention and subsequent intracellular localization
of ApoEmRNAmay be affected by cell type andmay impact its acces-
sibility to RNAi-mediated degradation.
DISCUSSION
In this study, we investigated the impact of different cell lines on
mRNA accessibly to and efficacy of RNAi. We observed significant
differences in siRNA efficacy between neuronal and astrocytic cell
lines when targeting ApoE. We further show that neuronal cells
have lower expression of ApoE mRNA, with predominantly nuclear
localization, potentially contributing to the reduced accessibility to
RNAi compared to astrocytic cells. Previous studies show that
ApoE mRNA and protein expression levels differ between cell types
and that inflammation and injury may activate neuronal ApoE
expression.11,12,26 Indeed, with the use of multiple assays, we found
that ApoE mRNA expression levels are much lower in neuronal cells
than astrocytic cells but still detectable using QuantiGene, qRT-PCR,
and RNA-seq.
So, what is the mechanism behind ApoEmRNA resistance to RNAi in
N2A cells? As the level of N2A ApoE is significantly lower compared
to astrocytes, one obvious explanation is that the detection of ApoE
mRNA is an artifact. To exclude this possibility, we evaluated ApoE
mRNA expression using four independent methodologies: Quanti-
Gene (signal to noise 10), qRT-PCR (raw cycle threshold [ct] value
29), RNA-seq (TPM: 8.1), and RNAscope (5–7 foci per cell). The
efficient detection of ApoE mRNA by multiple experimental ap-
proaches supports the notion that the low, but detectable, expression
of ApoE in N2A cells is not artificial.
siRNA therapeutics are becoming increasingly attractive as novel ap-
proaches for the treatment of genetically defined neurological dis-
eases.27 There is a body of literature on the optimal design and syn-
thesis of fully modified siRNAs,17,28,29 and prior to testing siRNAs
in animal models, efficacious sequences can be identified and
confirmed in cell-based models. However, there is minimal informa-
tion available on selecting optimal cell lines for screening siRNAs.
In general, it is believed that the nature of the cell line does not bias the
selection of efficacious siRNA compounds, and data generated in one
cell line will be comparable with others. There are rare examples of
varying single nucleotide polymorphisms between cell lines impact-
ing RNAi,30,31 but these sequence variations only impact the efficacy
of one particular siRNA candidate, not an entire panel.
Here, we show that even though ApoE mRNA is readily detectable,
thirty-five siRNAs targeting ApoE failed to induce silencing in N2A
cells. However, a large fraction of these compounds were active in pri-
mary astrocytes. Furthermore, despite lack of efficacy in N2A cells,
lead siRNA compounds targeting ApoE potently silenced ApoE
mRNA expression below the level of detection in mouse brains.32
Our results provide a potential explanation for discordance between
in vitro and in vivo efficacy previously reported,33 particularly if the
in vitro characteristics do not reflect endogenous conditions. There-
fore, it is crucial to select cell types that closely reflect the target cell
and tissue type in order to determine the properties of RNA expres-
sion, molecular pathology, and functionality of siRNAs.
Thus, this study identifies an additional troubleshooting step during
siRNA sequence screening: cell line selection and validation. Nonop-
timal selection of the cell line has the potential to skew results and
provide false negatives, causing in vitro efficacy data to not correlate
well with in vivo efficacy. At this point, it is hard to conclude how
widespread this phenomenon is. However, if the level of expression
of the target mRNA is relatively low, and siRNAs fail to functionally
reduce mRNA, then the selection of other cell lines or evaluation of
intracellular mRNA localization might be worth considering.
One other intriguing observation is the preferential localization of
neuronal ApoE mRNA to the nuclear compartment. The preferen-
tial nuclear localization of ApoE mRNA correlates with lack of
detectable protein expression and limited accessibility to RNAi. In
general, Ago2 is shown to be present and active both in the nucleus
and cytoplasm,34–36 but RNAi efficacy is believed to be more pro-
found and potent in cytoplasm. Thus, altered intracellular localiza-
tion might be, at least partially, responsible for lack of activity,
although it is unclear what the underlying cause of the observed
neuronal localization is.
Based on the RNA-seq data, N2A-expressed ApoE mRNA is pre-
dominately spliced (Figure 1D), which is similar to previously re-
ported results describing nuclear localization of HTT mRNA.37 In
general, only one to two foci are detected per nucleus, which map-
ped to the transcriptional sites.37 At this point, we do not have a
detailed understanding of the mechanism behind the observed nu-
clear retention of ApoE mRNA in N2A cells. Studies by Xu
et al.11,12 indicated that intron 3 inclusion in neurons resulted in
preferential nuclear retention and lack of protein translation.
With the examination of RNA-seq data for N2A cells, we do not
observe any detectable intron 3 retention (Figure 1D), and thus, it
is hard to conclude if the phenomena reported here are similar to
the one described by Xu et al.12 However, we did observe intron 1
retention in RNA-seq data for N2A cells compared to primary astro-
cytes, suggesting an additional mechanism that may be responsible
for lack of siRNA activity. Previous studies have reported that
altered splicing causes nuclear retention, storage, or protection of
mRNA, a mechanism that might apply here, and may impact the
functionality of RNAi.15 This phenomenon has been observed in
(APOE1134). (D) Quantification of ApoEmRNA foci after treatment with siRNAs. (E and F) Dose-dependent mRNA silencing of two lead siRNAs in (E) mouse N2A cells and (F)
primary astrocytes. (G) Dose-dependent protein silencing in primary astrocytes (bottom) and no effect in N2A cells (top). (H) Quantification of ApoEmRNA after treatment with
APOE1134. Left: N2A cells; right: primary astrocytes. Time point: 72 h. Scale bars, 10 mm. Statistical analysis: t-tests using GraphPad Prism. Error bars are SD. (**** p <0.0001;
*** p<0.002; ** p<0.01; * p<0.05).
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neuronal cells,15 with certain transcripts evading endogenous decay
methods and intron splicing occurring in response to stress signals15
and potentially contributing to neurodegenerative disease
phenotypes.38
Further studies are necessary to investigate the implication that the
majority of the detectable mRNA in neuronal-like cells may be in
an inactive state,12 that is, both not being translated into protein,
and is inaccessible to RNAi, potentially due to intron retention. In
addition, further investigation of the specific localization of ApoE
mRNA, i.e., localization with ribonucleoproteins (RNPs), RNA bind-
ing proteins (RBPs), or processing (P)-bodies,39–41 may provide
insight into the mechanisms behind resistance to RNAi observed
here.
The utility of an inactive pool of neuronal ApoE mRNA remains un-
clear and warrants further investigation; however, we show for the
first time the impact of this phenomenon on the development and ef-
ficacy of novel therapeutic strategies, such as RNAi.
It was recently shown that ApoE4 worsens tau pathology in human-
derived cell lines and that the toxicity is conferred specifically by
neuronal ApoE.26 Thus, the development of ApoE-targeted therapeu-
tics may require modalities that modulate ApoE in all cell types (as-
troglia, microglia, neurons, etc.) in the brain in order to see improve-
ment in neuropathology and cognition. Indeed, only complete genetic
knockout of brain ApoE (compared to 50% reduction with ASOs) in
mouse models of Alzheimer’s disease (AD) resulted in pathology
improvement.42–45 Thus, the understanding of how cell identity
and cell state may impact the response to these therapeutics is increas-
ingly important and may have implications that reach further than
cell-based screening studies and stretch throughout the drug-devel-
opment process.
MATERIALS AND METHODS
Ethics Statement
All national regulations and guidelines for the human care and use of
animals (including the timed pregnant mice used to obtain primary
neurons) were followed, and the animal procedures were approved
by the University of Massachusetts Medical School Institutional An-
imal Care and Use Committee (IACUC; Protocol #A2411).
Design and Synthesis of Chemically Modified siRNAs
We designed a panel of thirty-five siRNA compounds targeting the
mouse ApoE gene. The siRNA sequences span the entirety of the
ApoE mRNA and were designed according to the guidelines laid
out in Birmingham et al.17 Factors influencing the selection of se-
quences include optimal GC content, target specificity, low seed com-
plement frequency, removal of sequences containing toxicmotifs, and
removal of sequence containing microRNA (miRNA) seeds.
Oligonucleotide Synthesis
Oligonucleotides were synthesized using modified (2ʹ-fluoro [2ʹ-F],
2ʹ-O-methyl [2ʹ-O-Me]) phosphoramidites with standard protecting
groups (ChemGenes). Phosphoramidite solid-phase synthesis was
done on a MerMade 12 (BioAutomation) and Dr. Oligo 48 (Biolytic)
using modified protocols. Unconjugated oligonucleotides were syn-
thesized on controlled pore glass (CPG) functionalized with a long-
chain alkyl amine (LCAA) and unylinker terminus (ChemGenes).
Cholesterol-conjugated oligonucleotides were grown with the choles-
terol moiety bound to a tetraethylenglycol (TEG) attached through a
succinate linker to LCAA-CPG support (ChemGenes). Phosphorami-
dites were prepared at 0.1 M in anhydrous acetonitrile (ACN), with
added dry 15% dimethylformamide (DMF) in the 2ʹ-O-ME U ami-
dite. 5-(benzylthio)-1H-tetrazole (BTT) was used as the activator at
0.25 M. Detritylations were performed using 3% trichloroacetic acid
in dichloromethane (DCM). Capping was done with nontetrahydro-
furan-containing reagents CAP A, 20% n-methylimidazole in ACN;
and CAP B, 20% acetic anhydride (Ac2O), 30% 2,6-lutidine in
ACN (synthesis reagents were purchased at American International
Chemical [AIC]). Sulfurization was performed with 0.1 M solution
of 3-[(dimethylaminomethylene)amino]-3H-1,2,4-dithiazole-5-thi-
one (DDTT) in pyridine (ChemGenes) for 3 min. Phosphoramidite
coupling times were 3 min for all amidites used.
Deprotection and Purification of Oligonucleotides
All oligonucleotides were cleaved and deprotected using ammonium
hydroxide and 40% aqueous (aq.) methylamine (AMA) in a 1:1 ratio
for 2 h at room temperature. The oligonucleotide solutions were then
filtered to remove the CPG from the cleaved oligo. The filtrate was
then cooled with dry ice and then dried under vacuum in a SpeedVac.
The resulting pellets were resuspended in 5% ACN in water. The pu-
rification of the unconjugated strands were performed on an Agilent
1200 system, equipped with a Source 15Q anion exchange resin (GE
Healthcare; 10  100 mm custom-packed column), using the
following conditions: eluent A, 20% ACN, 20 mM sodium acetate
(pH 5); eluent B, 1 M sodium perchlorate in 20% ACN; gradient,
0% B 2 min, 35% B 12 min, clean, and re-equilibration to initial con-
ditions 6 min. Purification of cholesterol-conjugated strands was per-
formed on the same equipment but equipped with a PRP-C18 (Ham-
ilton), a polymer reverse-phase column (10  100 mm), using the
following conditions: eluent A, 50 mM sodium acetate in 5% ACN;
eluent B, ACN; gradient, 0% B 2 min, 0%–40% B 1 min, 40%–70%
B 9 min, clean, and re-equilibration 6 min. Temperature 70 C and
flow rate 40 mL/min were the same in both cases. Peaks were moni-
tored at 260 nm. The pure oligonucleotide fractions were collected,
individually characterized by liquid chromatography-mass spectrom-
etry (LC-MS), combined, frozen, and dried in a SpeedVac overnight.
Oligonucleotides were resuspended in 5% ACN and desalted through
fine Sephadex G-25 (GE Healthcare; 10  200 mm custom-packed
column) and lyophilized. All reagents mentioned above were pur-
chased from Sigma-Aldrich and used as per the manufacturer’s in-
structions, unless otherwise stated.
LC-MS Analysis of Oligonucleotides
The identity of oligonucleotides was established by LC-MS analysis
on an Agilent 6530 accurate mass Quadrupole Time of Flight (Q-
TOF) LC-MS, using the following conditions: buffer A, 100 mM
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hexafluoroisopropanol (HFIP)/9 mM triethylamine (TEA) in LC-
MS-grade water; buffer B, 100 mMHFIP/9mMTEA in LC-MS-grade
methanol; column, Agilent AdvanceBio Oligonucleotides C18;
gradient unconjugated strands 0% B 1 min, 0%–40% B 8 min, clean,
and re-equilibration 4 min; cholesterol-conjugated strands, 0% B
1 min, 0%–50% B 0.5 min, 50%–100% B 8 min, clean, and re-equili-
bration 4 min; temperature 45 C and flow rate 0.5 mL/min were the
same in both cases. LC peaks were monitored at 260 nm. MS param-
eters were the following: source, electrospray ionization; ion polarity,
negative mode; range, 100–3,200 mass-to-charge ratio (m/z); scan
rate, 2 spectra s1; capillary voltage, 4,000; fragmentor, 180 V. All re-
agents mentioned above were purchased from Sigma-Aldrich and
used as per the manufacturer’s instructions, unless otherwise stated.
Cell Culture
N2A cells (ATCC; CLL-131) were maintained in Eagle’s minimum
essential medium (ATCC; #30-2003), supplemented with 10% fetal
bovine serum (FBS; Gibco, Carlsbad, CA, USA; #26140) and 100 U/
mL penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA;
#15140), and grown at 37C and 5% CO2. Cells were split every 2–
5 days.
Preparation of Primary Astrocytes
Primary cortical astrocytes were obtained from C57BL/6J mouse em-
bryos at embryonic day 15. Pregnant C57BL/6J females were anesthe-
tized by inhalation of isoflurane, followed by cervical dislocation. Em-
bryos were removed and transferred to a Petri dish with ice-cold
Dulbecco’s modified Eagle’s medium. Brains were removed and
meninges detached. After isolation of cortices, brain tissue was me-
chanically disrupted using a surgical scalpel. Cortices were then
placed in 1.5 mL of TrypLE (Thermo Fisher Scientific; #12604013)
and incubated for 25 min at 37C and 5% CO2. The cortices were
dissociated with repetitive pipetting, as described above, and plated
in T-75 cm2 flasks in DMEM, supplemented with 10% FBS and
10 ng/mL of mouse epidermal growth factor. Astrocytes were allowed
to differentiate over 2 passages, cell identity was confirmed using glial
markers (glial fibrillary acidic protein [GFAP]), and cells were used in
assays. Dividing primary astrocytes were split every 5–7 days and dis-
carded after 10 passages.
Delivery and Silencing with siRNAs
Cells were plated in respective media, supplemented with 6% FBS at
10,000 cells per well (50 mL/well), in 96-well tissue-culture plates.
siRNA was diluted to twice the final concentration in Opti-MEM
(Gibco; #31985-088). 50 mL siRNA was added to 50 mL of cells, result-
ing in 3% FBS in the media. Cells were incubated for 72 h at 37C and
5% CO2. Primary screens were performed at 1.5 mM compound dose.
mRNA Quantification: QuantiGene
mRNA and mRNA silencing were quantified using the QuantiGene
2.0 Assay (Affymetrix; #QS0011) and as described in Coles et al.19
and Alterman et al.18 Cells were prepared, as previously described,
and probe sets were diluted, as specified in the Affymetrix protocol.
The following probe sets were used: mouse ApoE (SB-13611) and
mouse PPIB (SB-10002). Briefly, RNA-specific probe sets were added
to precoated plates, followed by sample lysates. The probe sets and
samples hybridized overnight, followed by three amplification steps
that provided a high signal-to-noise ratio.
mRNA Quantification: qRT-PCR
RNA was purified from cells or tissue using QIAGEN RNeasy (-
QIAGEN; #74194) and performed as specified by the manufacturer.
cDNA was generated from up to 1 mg of purified RNA using the
High-Capacity Reverse Transcription Kit (Thermo Fisher Scientific;
#4368813). qPCR was performed using iTaq Universal SYBR Green
Supermix (Bio-Rad; #1725120) following the manufacturer’s instruc-
tions. Primers for mouse ApoE can be found in Table S3.
Analysis of RNA-Seq Datasets
Previously published datasets were used to analyze ApoE expression
in N2A cells (GSE45119)20 and primary mouse cortex
(GSE52564)21. RNA-seq analysis was performed using the RNA-seq
pipeline on DolphinNext (https://dolphinnext.umassmed.edu/).46
Briefly, raw reads were aligned to the mm10 genome using Spliced
Transcripts Alignment to a Reference (STAR),47 TPM quantification
was done using RNA-Seq by Expectation-Maximization (RSEM),48
and quality control was analyzed using an RNA-seq Quality Control
Package (RSeQC).49 Data were visualized using Integrative Genomics
Viewer (IGV).50,51
RNAscope FISH and FISH-Immunofluorescence (IF)
RNAscope probe sets for mouse ApoE and mouse Hprt were obtained
from ACDBio (#313271; #312951). RNAscope, using the RNAscope
Fluorescent Multiplex Kit (ACDBio; #320850), was performed
following the manufacturer’s instructions. Dual FISH-IF was used to
detect NeuN and GFAP. RNAscope was performed as described in
the protocol, followed directly by IF. Samples were incubated for 1 h
in blocking solution (2% normal goat serum, 0.01% Triton X in PBS)
at room temperature. Samples were washed 3 times for 5 min in PBS
and incubated in primary antibodies diluted in blocking solution
(anti-NeuN 1:200 #MAB377; anti-GFAP). Slides were washed 3 times
for 5 min in PBS and incubated for 1 h at room temperature in Alexa
Fluor secondary antibodies (1:800; Thermo Fisher Scientific). Samples
were washed 3 times for 5 min in PBS, mounted in ProLong Diamond
Antifade (Thermo Fisher Scientific; #P10144), and dried overnight.
Imaging
Images were acquired with a CSU10B Spinning Disk Confocal System
scan head (Solamere Technology Group, Salt Lake City, UT, USA),
mounted on a TE-200E2 inverted microscope (Nikon, Tokyo, Japan)
with a 100 Plan/Apochromatic (APO) oil-immersion objective and
a CoolSNAPHQ2 camera (Roper Technologies, Sarasota, FL, USA). z
stacks were acquired in three different channels. Images were pro-
cessed using ImageJ software.
Western Blots
Western blots were performed using Wes by ProteinSimple, as
described in Alterman et al.32 Briefly, cell lysates were prepared in
www.moleculartherapy.org
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radioimmunoprecipitation assay (RIPA) buffer with protease inhibi-
tor cocktail. Total protein was quantified using the standard Bradford
assay. 1.2 mg of lysate, diluted in 0.1 sample buffer, was loaded into
the 16- to 230-kDa assay system. Anti-ApoE antibody (Abcam;
183597) was diluted 1:200 in antibody dilution buffer, and anti-
beta-actin antibody was diluted 1:25 in antibody dilution buffer.
The assay was performed according to the manufacturer’s
instructions.
Statistics
All statistics were performed using GraphPad Prism 8.
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